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Reply. In his comment on our recent paper describing
the phenotype of childhood-onset inflammatory bowel
disease (IBD), Dr Matary highlights several important
issues pertaining to the investigation and classification of
involvement of the upper gastrointestinal (GI) tract in
pediatric Crohn’s disease (CD).1,2 To enable a comparison
of the pediatric phenotype with adult-onset disease, we
used the Montreal classification of IBD rather than a
more detailed, anatomic classification of disease extent
which we have previously used in the genotype–pheno-
type analysis of NOD2/CARD15 variants.3 Our investi-
gation protocol based on the ESPGHAN Porto-criteria,
adhered to by the pediatric gastroenterologists at the 3
recruiting centers, states that biopsies are taken routinely
from the upper GI tract during the investigation of
pediatric IBD.4 Involvement of any anatomic location
was defined as either macroscopic, microscopic, or both.
Macroscopically, the minimum criteria for involvement
of a disease location were ulceration or the presence of an
aphthous lesion. Erythema and/or edema did not suffice
to score a site as affected by CD. Microscopically, non-
specific inflammation or inflammatory changes that
could be otherwise explained (eg, reflux esophagitis or
Helicobacter pylori gastritis) were not classified as CD.
Interobserver variability was addressed by the quality
control of phenotypic data by a dedicated database man-
ager (HED) after review of the case notes (including
endoscopy, pathology, and radiology reports).
The application of the recent Montreal classification,
which has addressed some of the difficulties of previous
systems in classifying pediatric IBD (specifically the in-
volvement of the upper GI tract, which precluded classi-
fication of lower GI disease in the Vienna classification),
makes comparisons with historical datasets trouble-
some.5,6 In these older datasets, as for example that de-
scribed in the study by Lenaerts et al,7 the upper GI tract
was typically not investigated in the absence of clear upper
GI-related symptoms, as acknowledged in their manuscript.
In the absence of clear upper GI symptoms, esophagogas-
troduodenoscopy is also rarely performed in the investiga-
tion of adult-onset CD.8 However, involvement of the upper
GI tract has been reported to be as high as 75% in prospec-
tive adult CD studies where esophagogastroduodenoscopy
was routinely performed.9,10 Furthermore, in the Montreal
classification, jejunal disease is scored as upper GI disease
(the L1 category is limited to ileal disease), which further
compromises comparison with older classification systems,
dividing the GI tract into the upper, small bowel, and colon.
Our finding that60% of children affected by Crohn’s
disease display involvement of the upper GI tract is,
therefore, comparable with contemporary prospective
studies in adult onset CD and further highlights the
importance of a comprehensive assessment of our pedi-
atric CD patients.
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In the January 2009 issue of GASTROENTEROLOGY, the Comment From
the Editor described 8 cohorts of patients with acute Hepatitis C in
North America in an effort to heighten awareness of this interesting
patient population. The following letters highlight additional unique
and valuable acute hepatitis C cohorts in North America and further
emphasize the important window of opportunity to identify at-risk
populations within correctional facilities. Collectively, these cohorts
provide important opportunities to better understand the epidemiol-
ogy, natural history, and effective therapeutic approaches of acute
hepatitis C in North America, as well as the early pathogenetic mech-
anisms.
Acute Hepatitis C Infection in
Correctional Settings
Dear Sir:
We greatly appreciated the recent spotlight on the
important epidemiologic, immunologic, and virologic re-
search that is ongoing in US cohorts of acute hepatitis C
infection.1 We would like to take this opportunity to
highlight an additional aspect of acute hepatitis C that is
evidenced in our work within the Massachusetts correc-
tional system, where we have initiated screening pro-
grams for acute hepatitis C virus (HCV) infection during
the medical intake examination for recently incarcerated
inmates. More than 3200 inmates have been screened
with a short questionnaire eliciting information regard-
ing high-risk behaviors. Through the help of medical
providers based in the correctional system, we have iden-
tified 140 subjects at high risk of infection; surpris-
ingly, 37 cases of acute HCV infection were subsequently
diagnosed over a 15-month period (manuscript in prep-
aration). These results demonstrate that, beyond the well-
known epidemic of chronic HCV in the correctional
system, there is also a high rate of acute HCV infection,
mainly among recently incarcerated new drug users.2
The Centers for Disease Control and Prevention man-
dated in 2003 that primary and secondary HCV preven-
tion efforts should be focused on injection drug users
and specifically cited prison facilities as an ideal setting
for such efforts.3 However, the feasibility and the accept-
ability of such interventions were unknown. Since 2006,
we have found widespread acceptance of our interven-
tions, including HIV testing and immunizations against
hepatitis A and B infection. We are examining the utility
of new algorithms of expanded diagnostic criteria for
acute HCV infection in new-onset injection drug users,
who often have no prior record of serologic testing. We
have also shown that treatment of acute HCV infection
in the prisons is feasible, safe, and effective. As noted in
our pilot project,4 we have found that the burden of most
new HCV infections is occurring in Caucasian subjects,
although there is wide representation of Hispanics and
blacks within our prison population. Furthermore, study
of these interesting trends is being planned.
Despite some exemplary exceptions,1 the diagnosis and
treatment of acute HCV in injection drugs users has been
generally low. However, our concentrated efforts within
the structured environment of the correctional setting
demonstrate that this avenue of intervention has high
yield among a largely underserved patient population.
Because more than half of US inmates are incarcerated
owing to new drug use offenses, there is indeed a “win-
dow of opportunity” to make a difference.5
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